AngioDynamics (NASDAQ:ANGO) Given Buy Rating at Canaccord Genuity Group

09 Oct 2026, 12:37 by Danessa Lincoln · The Markets Daily

AngioDynamics (NASDAQ:ANGO – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Canaccord Genuity Group in a research report issued on Friday, Benzinga reports. They presently have a $20.00 target price on the medical instruments supplier’s stock. Canaccord Genuity Group’s price target would indicate a potential upside of 81.23% from the stock’s previous close.

Several other research firms have also recently issued reports on ANGO. Wall Street Zen raised AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. HC Wainwright boosted their target price on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Finally, Zacks Research raised AngioDynamics from a “strong sell” rating to a “hold” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.50.

View Our Latest Stock Analysis on ANGO

AngioDynamics Stock Down 1.7%

Shares of NASDAQ ANGO traded down $0.19 during trading hours on Friday, reaching $11.04. 295,382 shares of the stock traded hands, compared to its average volume of 496,473. The company has a market capitalization of $464.06 million, a P/E ratio of -12.68 and a beta of 0.30. AngioDynamics has a 52-week low of $9.39 and a 52-week high of $16.29. The company’s 50-day simple moving average is $15.39 and its two-hundred day simple moving average is $13.11.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last announced its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. The company had revenue of $80.92 million for the quarter, compared to analysts’ expectations of $80.51 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, sell-side analysts forecast that AngioDynamics will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling at AngioDynamics

In related news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AngioDynamics

Several hedge funds have recently made changes to their positions in the company. Integrated Wealth Concepts LLC bought a new stake in shares of AngioDynamics during the second quarter valued at approximately $38,000. Corient Private Wealth LP bought a new stake in AngioDynamics in the second quarter worth $134,000. Public Employees Retirement System of Ohio bought a new stake in AngioDynamics in the second quarter worth $64,000. Bank of America Corp DE bought a new stake in AngioDynamics in the second quarter worth $4,490,000. Finally, Gallagher Fiduciary Advisors LLC bought a new stake in AngioDynamics in the second quarter worth $589,000. 89.43% of the stock is currently owned by institutional investors.

Key Headlines Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

Positive Sentiment: AngioDynamics reported fiscal Q1 revenue of $80.9 million, slightly above consensus, while adjusted EPS of $(0.04) beat expectations of $(0.11). Revenue increased 6.9% year over year, led by 13.2% growth in Med Tech sales. Auryon sales rose 14.7% and NanoKnife sales climbed 29.0%. AngioDynamics Fiscal Q1 Results
Positive Sentiment: The company reiterated fiscal 2027 revenue guidance of $336 million to $341 million and EPS guidance of $(0.29) to $(0.24), broadly in line with analyst expectations. Canaccord Genuity reaffirmed its Buy rating and maintained a $20 price target, implying substantial potential upside from the referenced $11.23 price. AngioDynamics Outlook
Neutral Sentiment: Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The appointment brings an experienced medical-technology executive to the company, but the leadership change introduces near-term execution uncertainty and contributed to the weak market reaction. CEO Appointment
Negative Sentiment: Despite improved results, AngioDynamics remains unprofitable, with a reported GAAP net loss and negative margins. The company used $15.3 million in operating cash during the quarter and held $34.0 million in cash at quarter-end, heightening concerns about profitability and liquidity. The unchanged guidance also failed to provide a stronger catalyst after the earnings release.

AngioDynamics Company Profile

(Get Free Report)

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.